Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

DUBLIN, Ireland, June 01, 2020 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that members of the Avadel management team will participate in a virtual fireside chat at the Jefferies Healthcare Conference at 10:00 a.m. ET on Thursday, June 4, 2020.
A live webcast of the event will be available at the “Investors” section of the Company’s website at www.avadel.com. A replay of the webcast will be available on Avadel’s website for 90 days following the presentation.Date: Thursday, June 4, 2020
Time: 10:00 a.m. ET
Presenters:
Greg Divis, Chief Executive OfficerJordan Dubow, M.D., Chief Medical OfficerThomas McHugh, Chief Financial Officer   About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel develops and markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com.
Contacts:Investor Contacts
Tom McHugh
Chief Financial Officer
Phone: (636) 449-1843
Email: [email protected]
             
Tim McCarthy
LifeSci Advisors, LLC
Phone: (212) 915.2564
Email: [email protected]
Media Contact
Patrick Bursey
LifeSci Communications, LLC
Phone: (646) 970-4688
Email: [email protected]


Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search